Vyleesi Accelerated Titration: How Fast Can You Increase Bremelanotide Dose?
HealthRX.com
Vyleesi has one fixed dose, so there is no titration to speed up
Key numbers
- 1.75 mgOnly approved Vyleesi dose, used as needed at least 45 minutes before sexual activitySource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 8 doses per monthLabel says more than 8 doses per month is not recommended, with one dose per 24 hoursSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 40.0%Nausea rate with Vyleesi in pooled trials, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 8 weeksLabel says to stop Vyleesi if symptoms have not improved after this timeSource: dailymed.nlm.nih.gov, as cited Nov 8, 2026
From the public record
FDA label facts for bremelanotide
The FDA label read for bremelanotide (Vyleesi, application NDA210557) was last revised on 2026-11-05. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2026-11-05 | |
| Label read | Vyleesi | NDA210557, brand-name application |
| Boxed warning | No | |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient bremelanotide from an original manufacturer
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
From the public record
Registered clinical studies of bremelanotide
ClinicalTrials.gov lists 10 registered studies that name bremelanotide as an intervention as of 2026-11-11. Of these, 0 are recruiting, 9 are completed and 3 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 10 |
| Recruiting now | 0 |
| Not yet recruiting | 0 |
| Completed | 9 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 (including phase 2/3) | 3 |
| Phase 2 (including phase 1/2) | 4 |
| Phase 1 | 1 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches bremelanotide, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
At a glance
- Approved dose / 1.75 mg subcutaneous autoinjector, fixed
- Titration steps / None: no lower or higher approved dose
- Minimum spacing / One dose per 24 hours
- Monthly ceiling / More than 8 doses per month not recommended
- Timing / At least 45 minutes before anticipated sexual activity
- Stop rule / Stop after 8 weeks if no improvement in symptoms
- Nausea, phase 3 / 40.0% vs 1.3% on placebo
- Contraindications / Uncontrolled hypertension or known cardiovascular disease
Is there an accelerated titration schedule for Vyleesi?
No. The label's dosage section gives one dose and one interval: 1.75 mg injected subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity [1]. It contains no step-up instruction, and no lower or higher dose is approved [1]. Vyleesi is supplied as a prefilled autoinjector pen and is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not indicated for men, for postmenopausal women, or to enhance sexual performance [1][2].
So there is nothing to escalate and nothing to speed through. The only choices a patient makes are when to use a dose and how often, inside the label's limits.
Questions worth asking
What the label allows: one dose, one interval, one monthly ceiling
The label permits one 1.75 mg dose in any 24 hours and states that more than 8 doses per month is not recommended [1]. Two reasons are given for the monthly limit: more frequent dosing increases the risk of focal hyperpigmentation and lengthens the time each month during which blood pressure is raised [1].
Timing within the day is partly left to the patient. The label says the duration of efficacy after each dose is unknown and that the optimal administration window has not been fully characterized, and that patients may decide the best time based on how they experience the duration of effect on desire and any adverse reactions such as nausea [1].
Does a second dose the same day work faster?
The label states that the efficacy of consecutive doses within 24 hours has not been established, and that giving doses close together may increase the risk of additive blood pressure effects [1]. It also says patients should not take more than one dose in 24 hours, to minimize the risk of more pronounced blood pressure effects [1].
For context on timing, a 1.75 mg subcutaneous dose produces a mean peak plasma concentration of 72.8 ng/mL, a median time to peak of about 1 hour and a mean half-life of about 2.7 hours (range 1.9 to 4.0) [1]. How long the effect on desire lasts after a dose is not known [1].
Can the dose go above 1.75 mg?
No higher dose is approved, and the label gives no escalation beyond 1.75 mg [1].
What limits frequency: blood pressure and pigmentation
Each dose transiently raises blood pressure and lowers heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with a heart rate reduction of up to 5 beats per minute; values usually returned to baseline within 12 hours [1]. Those are maximal, not average, figures. In an open-label ambulatory monitoring study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart rate decrease of 0.5 beats per minute [1]. Repeat daily dosing 24 hours apart for up to 16 days produced no additive blood pressure or heart rate effects [1].
Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease and is not recommended for patients at high risk of cardiovascular disease; the label asks that cardiovascular risk be considered and blood pressure be well controlled before starting and periodically during treatment [1].
Pigmentation is the other constraint. In the placebo-controlled trials, focal hyperpigmentation including the face, gums and breasts was reported by 1% of patients who received up to 8 doses a month, versus none on placebo [1]. Daily dosing changes that picture sharply: 38% of patients developed focal hyperpigmentation after 8 consecutive days of daily dosing, and a further 14% developed new pigmentary changes after 8 more days [1]. Patients with dark skin were more likely to develop it, resolution was not confirmed in all patients after stopping, and the label says to consider discontinuing Vyleesi if hyperpigmentation develops [1].
Nausea is what limits early use, not dose
Nausea was reported by 40% of Vyleesi-treated patients compared with about 1% on placebo; 13% needed anti-nausea medicine and 8% stopped the trials because of it [1]. In the pooled adverse reaction table the rates are 40.0% versus 1.3% [1]. It was most common after the first dose, reported by 21% of patients, then declined to about 3% with later doses, and the label notes that nausea improves for most patients with the second dose [1]. Overall, 18% of Vyleesi patients discontinued for adverse reactions versus 2% on placebo [1].
Pre-treatment has been tested with one drug, and it did not work. In a phase 4 single-dose study of 228 healthy women, 8 mg of oral ondansetron taken 30 minutes before a 1.75 mg dose did not reduce the incidence of nausea, and the label says it is not recommended; ondansetron given after the dose or after nausea begins has not been formally studied [1]. The label says to consider discontinuing Vyleesi for persistent or severe nausea, or starting anti-nausea treatment for patients who are bothered by it but want to continue [1].
In the 52-week open-label extension (a descriptive analysis with no placebo group), 684 of 856 eligible women enrolled and 272 completed; the most common drug-related events were nausea 40.4%, flushing 20.6% and headache 12.0% [3].
The 8-week check replaces the titration step
The label says to stop Vyleesi after 8 weeks if there is no improvement in symptoms [1]. That is the closest thing to a dose decision in the label, and it is a stop rule rather than an escalation. Efficacy data come from two identical 24-week trials: 1,267 premenopausal women were randomized, 1,247 were in the safety population and 1,202 in the efficacy analysis [4]. Versus placebo, Female Sexual Function Index desire-domain scores improved by 0.30 points in study 301 and 0.42 in study 302, with an integrated difference of 0.35 points (all P less than 0.001), and distress related to low desire fell by 0.37, 0.29 and 0.33 points on the FSDS-DAO item 13 (P less than 0.001, P=0.005 and P less than 0.001 respectively) [4]. The label reports FSFI-desire change from baseline as 0.5 versus 0.2 in study 1 and 0.6 versus 0.2 in study 2 [1]. There was no significant difference in the number of satisfying sexual events [4].
Compounded PT-141 is a different product
None of this carries over to products sold as compounded or research-use PT-141. Those are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [5][1]. For Vyleesi, the label's fixed 1.75 mg dose and 24-hour spacing, with more than 8 doses a month not recommended, make up the approved regimen [1].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Can you start Vyleesi at a lower dose and work up?
Can you take a second Vyleesi dose if the first one does not seem to work?
How many Vyleesi doses can you use in a month?
Does ondansetron prevent Vyleesi nausea?
How long before deciding Vyleesi is not working?
Does a higher bremelanotide dose work better?
References
Show all 5 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- Official web page.